Most 'cope' supplements tier list checked against evidence

Key points

• “Cope” is slang. In this post it appears to mean a product that supposedly does little. The post gives no definition or criteria, so the tiers are an opinion, not a finding [1].
• The list mixes dietary supplements, unapproved research peptides and prescription drugs. A prescription drug is chosen and monitored by a prescriber. The “cope” label for an SSRI, diazepam, pregabalin, Ritalin or finasteride is not evidence about those drugs [8][9][11][12][14].
• Where we found good evidence for an approved use, it contradicts “does little”: SSRIs, finasteride, methylphenidate and pregabalin all beat placebo in trials [8][10][13][15].
• Several low-tier items (creatine, ashwagandha, multivitamin) have randomized data with small to modest effects. Several peptides (MOTS-c, Semax, Selank, GHK-Cu injection) are unapproved and have little or no human data, so “does little” cannot be tested [22][2][27].
• For about a third of the list (sea moss, royal jelly, Vilon, Vesugen and others) we could not verify any trial evidence.

What “cope” means here

The post is a single image under the text “ranking the most cope supplements”. It had 685 likes and 288,572 views when we read it through the fxtwitter mirror on 2026-11-09 [1]. We did not view the image; the items below come from the project’s transcription of it. Rows run from “extremely cope” to “somewhat cope”.

“Cope” here is internet slang for something people take to feel better while it supposedly does nothing, a placebo-like crutch. The post does not say so, and it does not say whether “cope” means “ineffective”, “overhyped”, “unsafe” or “not worth the cost”. We test one thing: does the best available evidence support the idea that the item does little for its documented use? Verdicts use the brief’s scale: supported, partly supported, not supported, could not be verified.

Status is for the US unless stated. We did not check the EMA, MHRA or BfArM registers. “Not assessed” means we opened no study we could cite.

Extremely cope

Item	What it is	Status	Best evidence	“Does little”?
Ashwagandha	Herbal root extract	Sold as a dietary supplement; FDA does not approve supplements before sale [2]	Meta-analysis of 9 RCTs, 558 people: lower stress and anxiety scores and cortisol than placebo; 4 trials reported mild to moderate adverse events [3]. NCCIH: rare liver injury cases; avoid in pregnancy [2]	Not supported for stress scores; trials are small and use different extracts [2][3]
Cannabis	Plant, cannabinoids	Federal law: FDA has approved no marketing application for cannabis for any condition. Approved cannabinoid drugs: Epidiolex (seizures in Lennox-Gastaut or Dravet syndrome, age 2+), dronabinol and nabilone (chemotherapy nausea) [4]. On 23 Apr 2026 FDA-approved marijuana drugs and state-licensed medical marijuana moved to Schedule III; other marijuana stayed Schedule I, with a wider review pending (law-firm summary, 4 May 2026) [5]	Evidence is by product and condition, not for “cannabis” as a whole; we opened no review beyond the FDA drug list	Could not verify as a whole; approved products exist for specific conditions [4]
Phenibut	GABA-derived compound	FDA (April 2019): does not meet the definition of a dietary ingredient; supplements listing it are “misbranded” [6]. A 2025 lab survey says it requires a prescription in Russia [7]	We found no trial in our search; the recent literature was case reports, including a 2026 taper report [28]	Not assessed for efficacy. The regulatory tier is not about “does little”
Finasteride	5-alpha-reductase inhibitor	Prescription. Propecia 1 mg is approved for male pattern hair loss in men only (label dated 14 Oct 2024) [8]	Label trials: three 12-month placebo-controlled studies, 1,879 men aged 18-41; investigator rated 65% on drug as improved vs 37% on placebo; no efficacy shown in a 137-woman postmenopausal study [8]	Not supported for men’s hair loss. A prescriber decides on use [8]
SSRI	Antidepressant class, here read as the class	Prescription. Sertraline (Zoloft) is labelled for major depression, OCD, panic, PTSD, social anxiety and PMDD; boxed warning on suicidal thoughts in children and young adults [9]	Lancet 2018 network meta-analysis: 522 trials, 116,477 people; all 21 antidepressants beat placebo in adults with major depression; certainty moderate to very low [10]	Not supported for depression. Effect sizes and who benefits are debated; a prescriber decides [10]
Diazepam	Benzodiazepine	Prescription, Schedule IV. Valium is labelled for anxiety disorders, alcohol withdrawal, muscle spasm and as an adjunct in convulsive disorders; boxed warning on opioid co-use, abuse and dependence (label 1 Dec 2025) [11]	The label says effectiveness beyond 4 months has not been systematically studied [11]. We opened no trial	Could not verify beyond the label. A prescriber decides [11]

Very cope

Item	What it is	Status	Best evidence	“Does little”?
CLA	Fatty acid supplement	Sold as a dietary supplement; we did not check further	2024 meta-analysis, 70 trials, 4,159 adults: small reductions in body mass and fat mass; in high-quality trials the fat effect disappeared; authors say weight effects “may not reach clinical importance” [16]	Supported: effects are small
Multivitamin	Vitamin and mineral tablet	Dietary supplement (category as above)	COSMOS: in the clinic cohort (573 adults 60+, 2 years) a non-significant gain in global cognition and a significant gain in episodic memory. Pooled with two other COSMOS substudies, global cognition improved, about 2 years of cognitive ageing. Funders included NIH and Pfizer [17]	Partly supported: modest effects, one trial programme, older adults [17]
MOTS-c	Mitochondrial peptide	Unapproved. FDA lists it among withdrawn compounding nominations: no human exposure data identified [27]	Mouse and cell work; see our review for human studies	Could not verify. Too little human data to say it does little or much [27]
Pregabalin	Gabapentinoid	Prescription. Lyrica is labelled for diabetic and spinal-cord neuropathic pain, postherpetic neuralgia, fibromyalgia and partial seizures [12]	Cochrane 2019, 45 studies, 11,906 people: benefit in postherpetic neuralgia (NNTB 3.9 for 30% pain relief at 300 mg) and diabetic neuropathy (22 at 300 mg), none in HIV neuropathy; dizziness and somnolence more common [13]	Not supported for approved pain uses. A prescriber decides [12][13]
Kisspeptin-10	Reproductive peptide fragment	Unapproved. FDA Category 2 for compounding, citing limited safety information [27]	Small human studies on hormone levels; see our review	Could not verify as a supplement
Ritalin	Methylphenidate	Prescription, Schedule II. Labelled for ADHD in ages 6+ and adults, and narcolepsy; boxed warning on abuse and misuse (label 5 Feb 2025) [14]	Lancet Psychiatry 2018 network meta-analysis, 133 RCTs: in adults, symptom score SMD -0.49 vs placebo (95% CI -0.64 to -0.35); in children and adolescents -0.78 [15]	Not supported for ADHD. A prescriber decides [14][15]
Berberine	Plant alkaloid	Dietary supplement (category as above)	J Nutr 2023: 20 RCTs, 1,761 people, lower fasting glucose and HbA1c than placebo; subgroup claims rest on few trials [18]	Not supported for glucose measures; “modest” per the authors [18]

Pretty cope

Item	What it is	Status	Best evidence	“Does little”?
Sea moss	Seaweed	Not assessed	We opened no study	Could not verify
Vilon	Dipeptide (Lys-Glu)	Not on FDA’s bulk-substance list page [27]; not approved in the US or EU per our review	Small studies mostly from one research group; see our review of Khavinson peptides	Could not verify
Oxiracetam	Racetam-class drug	We did not check its status	2026 RCT: 500 adults, 36 weeks, post-stroke cognitive decline; no difference from placebo on MMSE (+0.13 vs +0.27) or CDR-SB; funded by Korean Drug Company [26]	Supported in that population, which is not healthy adults

Cope

Item	What it is	Status	Best evidence	“Does little”?
Ginkgo biloba	Leaf extract	Dietary supplement [20]	NCCIH (Feb 2025): GEM trial, over 3,000 people aged 75+, median 6 years, no difference in dementia; cognition benefit in healthy people uncertain [20]	Supported for dementia prevention; may be modest for dementia symptoms [20]
Lion’s mane	Mushroom	Dietary supplement	A 12-week placebo-controlled Japanese RCT reported better MMSE scores [24]; a 2019 conference abstract found 3 RCTs among 25 studies [25]. Mostly small	Partly supported: thin and small
Royal jelly	Bee product	Not assessed	PubMed lists 2025 placebo-controlled trials in other conditions; we opened none [28]	Could not verify
Semax	Russian peptide	Unapproved in the US; FDA lists it among withdrawn compounding nominations [27]. Prescription nasal drops in Russia per our review	Small Russian studies; see review	Could not verify
Selank	Russian peptide	Unapproved in the US; FDA lists “selank acetate” among withdrawn nominations [27]	Three small Russian studies; see review	Could not verify
Magnesium citrate	Mineral salt	Dietary supplement	2026 review of 12 RCTs on sleep: does not support routine use for insomnia; modest benefit on some subjective outcomes; certainty low to very low [19]	Partly supported for sleep

Somewhat cope

Item	What it is	Status	Best evidence	“Does little”?
Turmeric	Spice/curcumin	Dietary supplement	NCCIH (Apr 2025): not enough evidence for any health purpose; high-bioavailability products linked to liver injury [21]	Partly supported; safety signal is not trivial
Collagen peptides	Hydrolysed protein	Supplement or food	2026 meta-analysis of 19 RCTs, 1,341 people, on oral and topical peptides: improved hydration and brightness; elasticity inconsistent. It did not isolate collagen [23]	Not supported for skin hydration; evidence is mixed
Noopept	Synthetic dipeptide	Not an approved drug in the US to our knowledge; a 2025 lab survey calls it a prescription drug in Russia [7]	PubMed lists 106 records; the first ten were mostly animal work [28]	Could not verify in humans
Creatine monohydrate	Amino-acid derivative	Dietary supplement	2024 meta-analysis of 16 RCTs, 492 adults: better memory, attention time and processing speed; no difference in overall cognition or executive function; certainty moderate for memory [22]	Partly supported: small effects, short trials
GHK-Cu (injection)	Copper peptide	FDA lists the injectable route among withdrawn compounding nominations, citing immunogenicity [27]	Our review found no human trial of injection; topical studies are small	Could not verify
Vesugen	Tripeptide	Not on FDA’s bulk-substance list page [27]; not approved in the US or EU per our review	See review	Could not verify

Where the list and the evidence differ

1. The prescription drugs are not supplements. An SSRI, diazepam, pregabalin, Ritalin and finasteride each have an approved label with named uses and warnings. Their “cope” placement says nothing about whether they work for those uses. The documented evidence for their approved uses is trial-based: sertraline-class antidepressants, methylphenidate and pregabalin beat placebo in large reviews [10][13][15], and finasteride beat placebo in label trials [8]. Whether a drug suits a person is a prescriber’s decision, and we do not discuss non-medical use.

2. The unapproved peptides sit at the “cope” end for the wrong reason. MOTS-c, kisspeptin-10, Semax, Selank, GHK-Cu injection, Vilon and Vesugen have no approved product in the US. FDA says it found no human exposure data for MOTS-c and only limited safety data for several others [27]. “Does little” assumes an effect was measured. For these, mostly it was not.

3. Items with the clearest “does little” case are few. CLA (small effect), ginkgo for dementia prevention, oxiracetam in post-stroke cognition and magnesium for insomnia have trial data pointing to little or no effect [16][20][26][19]. Creatine, ashwagandha, berberine and multivitamin sit lower or higher than their data suggest: all have randomized evidence of small to modest effects [3][17][18][22].

4. “Cope” and safety are different questions. Turmeric appears at the mild end but NCCIH links high-bioavailability products to liver injury [21]. Ashwagandha, at the top, has the same type of rare liver signal [2].

Risks and unknowns

• We did not read the image. Names and tiers come from a transcription; spellings such as “Vesugen” and “Vilon” follow it.
• Efficacy for cannabis as a whole, diazepam beyond the label, phenibut, sea moss, royal jelly, Vilon, Vesugen, Semax and Selank was not assessed by us from primary trials. Where we link a review, its sources were not re-opened here.
• The cannabis rescheduling summary comes from a law-firm note (4 May 2026), not the Federal Register. We found no source on a final decision for adult-use marijuana.
• We did not check dietary supplement status on a manufacturer level, nor the UK, EU or German status of any item.
• Adverse effects: SSRI, diazepam, Ritalin and pregabalin labels carry boxed warnings or serious-risk sections. Interactions and populations at risk are on the labels and in prescriber guidance, not here. Ashwagandha and turmeric carry liver-injury reports; ginkgo can raise bleeding risk with anticoagulants [2][20][21].
• Reviews report averages. They cannot say whether an item works for a given person.

Frequently asked questions

What does “cope” mean in this tier list? It is slang for something people use that supposedly does little. The post gives no definition, so the label cannot be tested as a claim without choosing one. We tested whether the best evidence supports “does little” for each item’s documented use [1].

Is an SSRI really “extremely cope”? The label is an opinion. Sertraline is approved for several psychiatric conditions, and a 2018 network meta-analysis of 522 trials found all 21 antidepressants beat placebo in adult major depression, with moderate to very low certainty [9][10]. Prescribers decide who gets one.

Which items does the evidence support as low-impact? CLA, ginkgo for dementia prevention, magnesium for insomnia and oxiracetam in stroke survivors have trials showing small or no effects [16][20][19][26].

Why are the peptides hard to rank? MOTS-c, Semax, Selank, kisspeptin-10 and injected GHK-Cu are unapproved in the US, and FDA cites missing or limited human safety data [27]. Little human efficacy data exist, so the tiers are untested.

Sources

1. @Hoostethics, “ranking the most cope supplements” (X post, 15 Oct 2026; text and metrics read through the fxtwitter mirror; image transcribed in the project’s source file). https://x.com/Hoostethics/status/2110728908735979632
2. NCCIH, “Ashwagandha” (March 2023). https://www.nccih.nih.gov/health/ashwagandha
3. Arumugam V et al., Explore, “Effects of Ashwagandha (Withania Somnifera) on stress and anxiety: A systematic review and meta-analysis” (2024). https://pubmed.ncbi.nlm.nih.gov/39348746/
4. FDA, “FDA and Cannabis: Research and Drug Approval Process” (content current 24 Feb 2023). https://www.fda.gov/news-events/public-health-focus/fda-and-cannabis-research-and-drug-approval-process
5. DLA Piper, “DEA rescheduling of marijuana: initial steps taken, broader Schedule III review pending” (4 May 2026). https://www.dlapiper.com/insights/publications/2026/05/dea-rescheduling-of-marijuana-initial-steps-taken-broader-schedule-iii-review-pending
6. FDA, “FDA acts on dietary supplements containing DMHA and phenibut” (constituent update 16 Apr 2019). https://www.fda.gov/food/hfp-constituent-updates/fda-acts-dietary-supplements-containing-dmha-and-phenibut
7. Vanhee C et al., J Xenobiot, market surveillance of illicit nootropics in Europe and Australia (2025). https://pubmed.ncbi.nlm.nih.gov/40558871/
8. Organon, Propecia label, via openFDA drug label API (effective 14 Oct 2024). https://api.fda.gov/drug/label.json?search=openfda.brand_name:%22propecia%22
9. Viatris, Zoloft label, via openFDA drug label API (record accessed 2026-11-09). https://api.fda.gov/drug/label.json?search=openfda.brand_name:%22zoloft%22
10. Cipriani A et al., Lancet, “Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder” (2018). https://pubmed.ncbi.nlm.nih.gov/29477251/
11. Roche, Valium label, via openFDA (effective 1 Dec 2025). https://api.fda.gov/drug/label.json?search=openfda.brand_name:%22valium%22
12. Pfizer, Lyrica label, via openFDA (record accessed 2026-11-09). https://api.fda.gov/drug/label.json?search=openfda.brand_name:%22lyrica%22
13. Derry S et al., Cochrane Database Syst Rev, “Pregabalin for neuropathic pain in adults” (2019). https://pubmed.ncbi.nlm.nih.gov/30673120/
14. Sandoz, Ritalin label, via openFDA (effective 5 Feb 2025). https://api.fda.gov/drug/label.json?search=openfda.brand_name:%22ritalin%22
15. Cortese S et al., Lancet Psychiatry, “Comparative efficacy and tolerability of medications for ADHD” (2018). https://pubmed.ncbi.nlm.nih.gov/30097390/
16. Asbaghi O et al., Br J Nutr, CLA supplementation and body composition, dose-response meta-analysis (2024). https://pubmed.ncbi.nlm.nih.gov/37671495/
17. Vyas CM et al., Am J Clin Nutr, multivitamin-mineral and cognition, COSMOS-Clinic and meta-analysis (2024). https://pubmed.ncbi.nlm.nih.gov/38244989/
18. Zhao JV et al., J Nutr, berberine and glycemic and insulin-related traits (2023). https://pubmed.ncbi.nlm.nih.gov/37598753/
19. Lopresti AL et al., J Diet Suppl, “Magnesium Supplementation for Sleep in Adults: A Systematic Review of Randomized Controlled Trials” (2026). https://pubmed.ncbi.nlm.nih.gov/42661485/
20. NCCIH, “Ginkgo” (February 2025). https://www.nccih.nih.gov/health/ginkgo
21. NCCIH, “Turmeric” (April 2025). https://www.nccih.nih.gov/health/turmeric
22. Xu C et al., Front Nutr, creatine and cognitive function in adults (2024). https://pubmed.ncbi.nlm.nih.gov/39070254/
23. Nukaly HY et al., Front Med, oral and topical peptides for skin aging (2026). https://pubmed.ncbi.nlm.nih.gov/41924746/
24. Saitsu Y et al., Biomed Res, Hericium erinaceus and cognitive function (2019). https://pubmed.ncbi.nlm.nih.gov/31413233/
25. Nkodo A, Curr Dev Nutr, systematic review of dietary mushroom supplementation for cognitive impairment, conference abstract (2019). https://pmc.ncbi.nlm.nih.gov/articles/PMC6574952
26. Lim JS et al., Eur Stroke J, oxiracetam and physical activity after stroke (2026). https://pubmed.ncbi.nlm.nih.gov/41614470/
27. FDA, “Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks” (content current 22 Apr 2026). https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks
28. PubMed and Europe PMC searches run 2026-11-09 (terms: noopept; oxiracetam; royal jelly; Hericium erinaceus; phenibut). https://pubmed.ncbi.nlm.nih.gov/

This article is information, not medical advice.